Revenue
$2.58B
Fiscal year ended 2025-12-31Operating income
$47.20M
Fiscal year ended 2025-12-31Free cash flow
$374.60M
Fiscal year ended 2025-12-31BIO-RAD LABORATORIES, INC. (BIO) reported revenue of $2.58B and net income of $759.90M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIO-RAD LABORATORIES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B | $2.31B | $2.29B | $2.16B | $2.07B |
| Cost of revenue | $1.24B | $1.19B | $1.24B | $1.23B | $1.28B | $1.11B | $1.05B | $1.07B | $972.45M | $929.74M |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B | $1.44B | $1.26B | $1.22B | $1.19B | $1.14B |
| Operating income | $47.20M | $269.00M | $337.80M | $482.60M | $500.34M | $421.33M | $229.66M | -$103.34M | $119.25M | $55.72M |
| Net income | $759.90M | -$1.84B | -$637.30M | -$3.63B | $4.25B | $3.81B | $1.76B | $365.61M | $122.25M | $26.00M |
| Research & development | $275.60M | $295.90M | $247.40M | $256.90M | $260.64M | $217.76M | $202.71M | $199.20M | $250.16M | $205.71M |
| Weighted-average diluted shares | shares 27.28M | shares 28.21M | shares 29.21M | shares 29.78M | shares 30.21M | shares 30.16M | shares 30.18M | shares 30.23M | shares 30.03M | shares 29.65M |
| Pretax income | $995.50M | -$2.34B | -$850.10M | -$4.70B | $5.45B | $4.92B | $2.26B | $512.66M | $97.80M | $41.56M |
| Income tax expense | $235.60M | -$498.30M | -$212.80M | -$1.08B | $1.19B | $1.10B | $502.41M | $147.04M | -$24.44M | $15.56M |
| Diluted EPS | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.83 | $126.47 | $58.27 | $12.10 | $4.07 | $0.88 |
| Selling, general & administrative | $844.30M | $814.00M | $841.70M | $827.80M | $877.12M | $798.80M | $824.62M | $834.78M | $806.79M | $814.70M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $529.80M | $488.10M | $403.80M | $434.20M | $470.78M | $662.20M | $660.67M | $431.53M | $383.82M | $456.26M |
| Total assets | $10.58B | $9.36B | $12.30B | $13.50B | $17.80B | $12.97B | $8.01B | $5.61B | $4.27B | $3.85B |
| Current assets | $2.91B | $3.03B | $3.05B | $3.16B | $1.99B | $2.14B | $2.18B | $2.02B | $1.98B | $1.84B |
| Total liabilities | $3.12B | $2.79B | $3.56B | $3.89B | $4.11B | $3.09B | $2.25B | $1.59B | $1.34B | $1.27B |
| Current liabilities | $517.00M | $467.80M | $522.80M | $568.71M | $680.94M | $631.54M | $905.50M | $450.80M | $502.70M | $471.32M |
| Total equity incl. NCI | $7.45B | $6.57B | $8.74B | $9.62B | $13.69B | $9.89B | $5.76B | $4.02B | $2.93B | $2.58B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $740.70M | $760.00M | $780.50M | $719.32M | $572.24M | $622.25M | $554.01M | $583.82M | $594.80M | $524.96M |
| Accounts receivable | $460.60M | $452.50M | $489.00M | $494.64M | $423.54M | $419.42M | $392.67M | $392.44M | $464.85M | $372.35M |
| Goodwill | $579.80M | $410.50M | $413.60M | $406.50M | $347.30M | $291.90M | $264.10M | $219.80M | $506.10M | $477.10M |
| Long-term debt | $1.20B | $1.20B | $1.20B | $1.20B | $10.51M | $12.26M | $13.58M | $438.94M | $434.58M | $434.19M |
| Accounts payable | $129.00M | $122.30M | $144.60M | $135.04M | $141.94M | $139.45M | $107.01M | $122.45M | $135.18M | $133.11M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $532.20M | $455.20M | $374.90M | $194.40M | $669.46M | $584.97M | $457.90M | $285.49M | $104.14M | $216.07M |
| Capital expenditures | $157.60M | $165.60M | $156.70M | $112.80M | $133.75M | $108.56M | $98.53M | $129.82M | $111.33M | $141.44M |
| Investing cash flow | -$189.70M | -$160.20M | $20.20M | -$1.21B | -$797.38M | -$69.89M | -$208.89M | -$186.98M | -$175.57M | -$213.88M |
| Financing cash flow | -$283.20M | -$218.80M | -$425.60M | $973.60M | -$55.43M | -$523.04M | -$22.76M | -$48.68M | $341.00K | $9.02M |
| Net change in cash | $42.40M | $85.40M | -$30.10M | -$36.60M | -$195.98M | $4.46M | $228.49M | $49.18M | -$72.44M | -$1.28M |
| Stock-based compensation | $58.00M | $62.30M | $61.30M | $60.90M | $51.20M | $41.60M | $35.60M | $27.80M | $23.40M | $19.70M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $295.50M | $203.60M | $428.70M | $215.70M | $50.00M | $100.00M | $28.00M | $48.91M | $2.92M | $0 |
| Depreciation & amortization | $165.40M | $151.60M | $145.90M | $137.30M | $137.60M | $138.60M | $134.20M | $138.10M | $148.70M | $142.90M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $374.60M | $289.60M | $218.20M | $81.60M | $535.72M | $476.41M | $359.36M | $155.67M | -$7.20M | $74.63M |
| Gross margin | 51.9% | 53.7% | 53.4% | 55.9% | 56.1% | 56.5% | 54.4% | 53.4% | 55.0% | 55.0% |
| Operating margin | 1.8% | 10.5% | 12.6% | 17.2% | 17.1% | 16.6% | 9.9% | -4.5% | 5.5% | 2.7% |
| FCF margin | 14.5% | 11.3% | 8.2% | 2.9% | 18.3% | 18.7% | 15.5% | 6.8% | -0.3% | 3.6% |
| SBC / revenue | 2.2% | 2.4% | 2.3% | 2.2% | 1.8% | 1.6% | 1.5% | 1.2% | 1.1% | 1.0% |
| Current ratio | 5.62x | 6.48x | 5.83x | 5.55x | 2.92x | 3.39x | 2.41x | 4.49x | 3.93x | 3.91x |
| Revenue YoY growth | 0.7% | -3.9% | -4.7% | -4.1% | 14.8% | 10.1% | 1.0% | 6.0% | 4.4% | Unavailable |
| Net margin | 29.4% | -71.9% | -23.9% | -129.5% | 145.6% | 149.8% | 76.1% | 16.0% | 5.7% | 1.3% |
| R&D / revenue | 10.7% | 11.5% | 9.3% | 9.2% | 8.9% | 8.6% | 8.8% | 8.7% | 11.6% | 9.9% |
| CapEx / revenue | 6.1% | 6.5% | 5.9% | 4.0% | 4.6% | 4.3% | 4.3% | 5.7% | 5.2% | 6.8% |
| Long-term debt / equity | 0.16x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 23.7% | Unavailable | Unavailable | Unavailable | 21.9% | 22.4% | 22.2% | 28.7% | -25.0% | 37.4% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BIO in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-13View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-01View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.